CompletedPHASE2, PHASE3NCT00445575
Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone
Studying Fibrous dysplasia of bone
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Principal Investigator
- ROLAND D CHAPURLAT, MD PhDInstitut National de la Santé Et de la Recherche Médicale, France
- Intervention
- risedronate(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 8 years · All sexes
- Timeline
- 2007 – 2017
Study locations (8)
- Cliniques Universitaires Saint Luc, Brussels, Belgium
- Hopital E Herriot, Lyon, France
- Hopital Lariboisiere, Paris, France
- Hopital Cochin, Paris, France
- Hospital Benjamin Franklin, Berlin, Germany
- Cologne Clinical Centre, Cologne, Germany
- Heildeberg Clinical Centre, Heidelberg, Germany
- Leids Universitair Medisch Centrum, Leiden, Netherlands
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Charite University, Berlin, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00445575 on ClinicalTrials.govOther trials for Fibrous dysplasia of bone
Additional recruiting or active studies for the same condition.